Therapeutic strategies for human microsporidia infections

Area of Science:

• Medical Parasitology
• Infectious Diseases
• Drug Discovery

Background:

• Microsporidia, obligate intracellular parasites, are recognized as emerging pathogens in diverse human populations including AIDS patients and organ transplant recipients.
• Common human-pathogenic species include Enterocytozoon bieneusi and Encephalitozoon spp., causing diarrhea and systemic illness.
• Environmental and animal reservoirs raise concerns for waterborne, foodborne, and zoonotic transmission of microsporidiosis.

Purpose of the Study:

• To review the current understanding of microsporidia as human pathogens.
• To discuss existing therapeutic options for microsporidiosis and their limitations.
• To highlight emerging therapeutic strategies targeting microsporidia.

Main Methods:

• Literature review of microsporidia epidemiology, pathogenesis, and treatment.
• Analysis of current drug therapies, including albendazole and fumagillin.
• Summary of recent research on novel drug targets and compounds.

Main Results:

• Microsporidia infections pose a growing health concern across various demographics.
• Albendazole is effective against some Encephalitozoon species but less so against Enterocytozoon bieneusi.
• Fumagillin shows broader efficacy but exhibits systemic toxicity in mammals.

Conclusions:

• Current treatments for microsporidiosis have limitations in efficacy and safety.
• Novel therapeutic approaches targeting microsporidia-specific pathways, such as polyamines, methionine aminopeptidase 2, chitin synthesis, topoisomerases, and tubulin, are under investigation.
• Further research is crucial for developing effective and safe treatments for microsporidiosis.